AR074466A1 - Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3. - Google Patents
Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3.Info
- Publication number
- AR074466A1 AR074466A1 ARP090104666A ARP090104666A AR074466A1 AR 074466 A1 AR074466 A1 AR 074466A1 AR P090104666 A ARP090104666 A AR P090104666A AR P090104666 A ARP090104666 A AR P090104666A AR 074466 A1 AR074466 A1 AR 074466A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- receptors
- pirrolidinona
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Más específicamente estos compuestos son moduladores de los receptores H3 y, por lo tanto, son útiles como agentes farmacéuticos, especialmente en el tratamiento y/o prevención de una variedad de enfermedades moduladas por los receptores H3, incluyendo enfermedades asociadas con el sistema nervioso central. Reivindicación 1: Un compuesto de fórmula (1) donde m es 1 o 2; n es 1 o 2; p es 1 o 2; R1 es hidrógeno, alquilo C1-4, CF3, alcoxi C1-4-alquilo C1-4, R2 es hidrógeno, halógeno, alquilo C1-4 o CF3; y R3 es hidrógeno, alquilo C1-4, alquil C1-6oxicarbonilo, cicloalquil C3-7-alquilo C1-6, heterociclo sustituido o sin sustituir, heterocicloalquilalquilo C1-6 sustituido o sin sustituir, anillo de 5 o 6 miembros heteroarilalquilo C1-6 sustituido o sin sustituir, bencilo sustituido o sin sustituir, alcoxi C1-4-metilcarbonilo, cicloalcano C3-7-carbonilo sustituido o sin sustituir, bencilcarbonilo sustituido o sin sustituir, aril C6-10-carbonilo sustituido o sin sustituir, anillo de 5 o 6 miembros heteroarilcarbonilo sustituido o sin sustituir, heterociclocarbonilo sustituido o sin sustituir, bencenosulfonilo sustituido o sin sustituir, donde los sustituyentes se seleccionan de halógeno, trifluorometoxi, alcoxi C1-4, alquilo C1-4 o CF3; o un enantiómero o un diastereómero del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12008808P | 2008-12-05 | 2008-12-05 | |
| FR0955431 | 2009-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074466A1 true AR074466A1 (es) | 2011-01-19 |
Family
ID=41647030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104666A AR074466A1 (es) | 2008-12-05 | 2009-12-03 | Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3. |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8227481B2 (es) |
| EP (1) | EP2373652B1 (es) |
| JP (1) | JP5538421B2 (es) |
| KR (1) | KR101687216B1 (es) |
| CN (1) | CN102239168B (es) |
| AR (1) | AR074466A1 (es) |
| AU (1) | AU2009322248B2 (es) |
| CA (1) | CA2745721C (es) |
| CO (1) | CO6390058A2 (es) |
| CR (1) | CR20110294A (es) |
| DK (1) | DK2373652T3 (es) |
| EC (1) | ECSP11011108A (es) |
| ES (1) | ES2441221T3 (es) |
| IL (1) | IL213290A (es) |
| MA (1) | MA32943B1 (es) |
| MX (1) | MX2011004939A (es) |
| NZ (1) | NZ593151A (es) |
| PE (1) | PE20120261A1 (es) |
| PT (1) | PT2373652E (es) |
| RU (1) | RU2011127401A (es) |
| TN (1) | TN2011000233A1 (es) |
| TW (1) | TWI481609B (es) |
| WO (1) | WO2010065803A1 (es) |
| ZA (1) | ZA201103448B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR074467A1 (es) | 2008-12-05 | 2011-01-19 | Sanofi Aventis | Tetrahidropiran espiro pirrolidinonas y piperidinonas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento y/o prevencion de enfermedades del snc ,tales como alzheimer y parkinson, entre otras. |
| JP5968307B2 (ja) | 2010-05-11 | 2016-08-10 | サノフイ | 置換フェニルシクロアルキルピロリジン（ピペリジン）スピロラクタム類及びアミド類、それらの製造及び治療的使用 |
| TW201206901A (en) | 2010-05-11 | 2012-02-16 | Sanofi Aventis | Substituted N-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof |
| EP2569303A1 (en) | 2010-05-11 | 2013-03-20 | Sanofi | Substituted n-alkyl and n-acyl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof |
| TW201206444A (en) | 2010-05-11 | 2012-02-16 | Sanofi Aventis | Substituted N-heteroaryl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof |
| AR081382A1 (es) | 2010-05-11 | 2012-08-29 | Sanofi Aventis | Derivados de n-heterocicloalquil bipirrolidinilfenil amida sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades del sistema nervioso central. |
| EP2569304A1 (en) * | 2010-05-11 | 2013-03-20 | Sanofi | Substituted n-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof |
| EP2569296A1 (en) * | 2010-05-11 | 2013-03-20 | Sanofi | Substituted n-phenyl spirolactam bipyrrolidines, preparation and therapeutic use thereof |
| US9708270B2 (en) | 2012-10-11 | 2017-07-18 | Merck Sharp & Dohme Corp. | Substituted spiropiperidinyl compounds useful as GPR120 agonists |
| US9197285B2 (en) * | 2012-12-20 | 2015-11-24 | Deere & Company | Methods and apparatus for ameliorating signal reception |
| WO2019089868A1 (en) * | 2017-11-03 | 2019-05-09 | Bristol-Myers Squibb Company | Diazaspiro rock inhibitors |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3256276A (en) | 1961-02-17 | 1966-06-14 | Geschickter Fund Med Res | Substituted spiroimides |
| FR2816940A1 (fr) | 2000-11-23 | 2002-05-24 | Lipha | Derives de 4-(biphenylcarbonylamino)-piperidine, compositions les contenant et leur utilisation |
| EP1542667B1 (en) * | 2002-07-24 | 2012-03-07 | PTC Therapeutics, Inc. | Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| AU2003287206A1 (en) * | 2002-10-23 | 2004-05-13 | Janssen Pharmaceutica, N.V. | Phenylpiperidines and phenylpyrrolidines as histamine h3 receptor modulators |
| DE10306250A1 (de) * | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US7223788B2 (en) | 2003-02-14 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments |
| JP4524550B2 (ja) | 2003-08-19 | 2010-08-18 | オイレス工業株式会社 | 摺動部材用樹脂組成物および摺動部材 |
| JP4765627B2 (ja) | 2003-09-22 | 2011-09-07 | Ｍｓｄ株式会社 | 新規ピペリジン誘導体 |
| BRPI0608653A2 (pt) * | 2005-04-01 | 2010-11-30 | Lilly Co Eli | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou um sal do mesmo |
| AR057965A1 (es) | 2005-12-05 | 2007-12-26 | Incyte Corp | Compuestos de lactama y metodos de uso de los mismos |
| DE602006014305D1 (de) * | 2005-12-16 | 2010-06-24 | Hoffmann La Roche | Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors |
| AU2007214709A1 (en) * | 2006-02-15 | 2007-08-23 | Sanofi-Aventis | Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments |
| US20080247964A1 (en) | 2006-05-08 | 2008-10-09 | Yuelian Xu | Substituted azaspiro derivatives |
| EP2049473A2 (en) | 2006-06-29 | 2009-04-22 | Janssen Pharmaceutica N.V. | Substituted benzyl amine compounds |
| WO2008142859A1 (ja) * | 2007-05-18 | 2008-11-27 | Kowa Company, Ltd. | 新規なスピロオキシインドール化合物及びこれを含有する医薬 |
| CL2008001839A1 (es) | 2007-06-21 | 2009-01-16 | Incyte Holdings Corp | Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades. |
| US20100317679A1 (en) * | 2007-09-21 | 2010-12-16 | Ligand Pharmaceuticals, Inc. | Substituted aryl-fused spirocyclic amines |
| ES2372332T3 (es) | 2007-10-17 | 2012-01-18 | Sanofi | N-fenil-bipirrolidina carboxamidas sustituidas y su uso terapéutico. |
| MX2010004003A (es) * | 2007-10-17 | 2010-04-30 | Sanofi Aventis | N-fenil-pirrolidinilmetlipirrolidin amidas sustituidas y uso terapeutico de las mismas. |
| JP5255644B2 (ja) * | 2007-10-17 | 2013-08-07 | サノフイ | 置換されたｎ−フェニル−ビピロリジンカルボキサミド及びその治療上の使用 |
| AP2011005725A0 (en) | 2008-11-23 | 2011-06-30 | Pfizer | Lactams as beta secretase inhibitors. |
| AR074467A1 (es) | 2008-12-05 | 2011-01-19 | Sanofi Aventis | Tetrahidropiran espiro pirrolidinonas y piperidinonas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento y/o prevencion de enfermedades del snc ,tales como alzheimer y parkinson, entre otras. |
-
2009
- 2009-12-03 AR ARP090104666A patent/AR074466A1/es not_active Application Discontinuation
- 2009-12-04 EP EP09793649.6A patent/EP2373652B1/en active Active
- 2009-12-04 RU RU2011127401/04A patent/RU2011127401A/ru not_active Application Discontinuation
- 2009-12-04 ES ES09793649.6T patent/ES2441221T3/es active Active
- 2009-12-04 MX MX2011004939A patent/MX2011004939A/es active IP Right Grant
- 2009-12-04 AU AU2009322248A patent/AU2009322248B2/en not_active Ceased
- 2009-12-04 JP JP2011539716A patent/JP5538421B2/ja not_active Expired - Fee Related
- 2009-12-04 CN CN200980148493.0A patent/CN102239168B/zh not_active Expired - Fee Related
- 2009-12-04 PT PT97936496T patent/PT2373652E/pt unknown
- 2009-12-04 KR KR1020117015340A patent/KR101687216B1/ko active IP Right Grant
- 2009-12-04 CA CA2745721A patent/CA2745721C/en not_active Expired - Fee Related
- 2009-12-04 TW TW098141445A patent/TWI481609B/zh not_active IP Right Cessation
- 2009-12-04 WO PCT/US2009/066673 patent/WO2010065803A1/en active Application Filing
- 2009-12-04 PE PE2011001148A patent/PE20120261A1/es not_active Application Discontinuation
- 2009-12-04 MA MA33987A patent/MA32943B1/fr unknown
- 2009-12-04 DK DK09793649.6T patent/DK2373652T3/da active
- 2009-12-04 NZ NZ593151A patent/NZ593151A/xx not_active IP Right Cessation
-
2011
- 2011-05-11 TN TN2011000233A patent/TN2011000233A1/fr unknown
- 2011-05-11 ZA ZA2011/03448A patent/ZA201103448B/en unknown
- 2011-05-31 IL IL213290A patent/IL213290A/en not_active IP Right Cessation
- 2011-06-01 CR CR20110294A patent/CR20110294A/es unknown
- 2011-06-02 CO CO11068488A patent/CO6390058A2/es not_active Application Discontinuation
- 2011-06-02 US US13/151,946 patent/US8227481B2/en active Active
- 2011-06-03 EC EC2011011108A patent/ECSP11011108A/es unknown
-
2012
- 2012-06-19 US US13/527,147 patent/US8604046B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR074466A1 (es) | Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3. | |
| PE20171329A1 (es) | Agentes inmunorreguladores | |
| PE20221283A1 (es) | Compuestos triciclicos sustituidos | |
| PE20181269A1 (es) | Agonistas del receptor de apelina y metodos de uso | |
| PE20160546A1 (es) | Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4 | |
| PE20150230A1 (es) | Nuevos diazaespirocicloalcanos y azaespirocicloalcanos | |
| PE20171623A1 (es) | Agentes inmunomoduladores | |
| PE20200342A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue | |
| AR076274A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR106778A1 (es) | Derivados heterocíclicos activos como plaguicidas con sustituyentes que contienen azufre y ciclopropilo | |
| PE20120620A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
| PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
| PE20141682A1 (es) | Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio | |
| AR066210A1 (es) | Proceso para producir compuesto amida | |
| AR073406A1 (es) | Aminodihidrotiazinas fusionadas con tetrahidropiranos,inhibidoras de bace1 y de la produccion de abeta amiloide, composiciones farmaceuticas que las contienen y usos de las mismas para el tratamiento de enfermedades neurodegenerativas,tales como alzheimer. | |
| PE20130155A1 (es) | Derivados de ariletinilo | |
| AR061369A1 (es) | Derivados de pirimidina y composiciones farmaceuticas que los comprenden | |
| AR077227A1 (es) | Compuesto de acido aril/ heteroaril- sustituido carboxilico, su uso para fabricar un medicamento util el tratamiento de afecciones o trastornos mediados por receptores s1p1, tales como esclerosis multiple y composicion farmaceutica que lo comprende | |
| CL2012000516A1 (es) | Compuestos derivados de 3-[4-(4-(fenil/piridin/ pirimidin)- piperazin -1-il)-butil]-2, 3-dihidro-4h-croman-4-ona, moduladores del receptor de dopamina d3; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de un desorden neurologico o psiquiatrico, disfuncion erectil o dependencia a drogas, entre otros. | |
| UY37774A (es) | Compuestos 5-cianoindol sustituidos y usos de los mismos | |
| PE20091349A1 (es) | Compuestos derivados de espiro 1,3,4-tiadiazol como inhibidores de la actividad quinesina ksp | |
| AR050953A1 (es) | Compuestos de sulfonamida inhibidores de los receptores de cck1/cck2 duales | |
| PE20141556A1 (es) | Derivados de etinilo como moduladores alostericos de mglur5 | |
| AR104331A1 (es) | Derivados de tetrazol | |
| AR080703A1 (es) | Derivados de 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-carbazol, moduladores de receptores de prostaglandina d2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos alergicos o inmunitarios tales como asma. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |